In ovarian cancer cell lines, inhibition of EZH2 using DZNep (inhibitor of SAM dependent enzymes), EPZ6438 and GSK126 (selective inhibitor of EZH2) and DNMT (azacytadine) synergistically increase IFN-γ responsiveness, and CXCL9 and CXCL10 expression, while shrinking tumor size (165). Here, CXCL9 is linked to ovarian cancer.